Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)

James Chih Hsin Yang, Yuichiro Ohe, Chao Hua Chiu, Xiaoling Ou, Mireille Cantarini, Pasi A. Jänne, Ryan J. Hartmaier, Myung Ju Ahn

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science